Nord/LB Analysts Give Merck KGaA (FRA:MRK) a €94.00 Price Target

Merck KGaA (FRA:MRK) has been given a €94.00 ($109.30) target price by investment analysts at Nord/LB in a note issued to investors on Friday, Borsen Zeitung reports. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Nord/LB’s price objective indicates a potential downside of 0.91% from the stock’s current price.

Several other brokerages have also recently issued reports on MRK. Independent Research set a €106.00 ($123.26) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Wednesday, June 19th. Credit Suisse Group set a €110.00 ($127.91) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Thursday. Warburg Research set a €103.00 ($119.77) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Morgan Stanley set a €96.00 ($111.63) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, June 18th. Finally, Kepler Capital Markets set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Monday, June 17th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of €100.05 ($116.34).

FRA MRK traded up €0.30 ($0.35) during trading hours on Friday, reaching €94.86 ($110.30). The company’s stock had a trading volume of 484,060 shares. The business’s 50-day moving average is €93.46. Merck KGaA has a 1 year low of €76.60 ($89.07) and a 1 year high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: Key terms to understand channel trading

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.